Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.
AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.
September 24, 2024: Teva Pharmaceuticals presented new research demonstrating effective strategies for switching adult patients with schizophrenia from Perseris to Uzedy (risperidone extended-release.
US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.
HQ Team December 23, 2023: Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio,.
HQ Team, December 18, 2023: For individuals grappling with schizophrenia, the road to treatment is often marked by a lifelong commitment to antipsychotic.
HQ Team April 17, 2023: US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from.
